Black Diamond Therapeutics Inc expected to post a loss of 64 cents a share - Earnings Preview

Black Diamond Therapeutics

04/11/2022 18:52

* Black Diamond Therapeutics Inc  BDTX.OQ   BDTX.O  is
expected
to show no change in quarterly revenue when it reports 
results on November 7 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Black Diamond
Therapeutics Inc is for a loss of 64 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Black
Diamond
Therapeutics Inc is $4.5​, above​ its last closing price
of $2.33. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  -0.69       -0.68      -0.63     Beat    7.4
 Mar. 31 2022  -0.78       -0.75      -0.70     Beat    6.8
 Dec. 31 2021              -1.01      -0.71     Beat    29.9​
 Sep. 30 2021  -0.98       -0.98      -0.97     Beat    0.9
 ​​Jun.        -0.87       -0.84      -0.95     Missed  -13.1
 30 2021                                                
 Mar. 31 2021  -0.67       -0.68      -0.84     Missed  -23.7​
 Dec. 31 2020  -0.56       -0.63      -0.63     Met     0
 Sep. 30 2020  -0.51       -0.52      -0.50     Beat    4.6
 This summary was machine generated November 4 at 18:51 GMT.  All
figures in US dollars  unless otherwise stated